EC144 Is a Potent Inhibitor of the Heat Shock Protein 90

被引:54
|
作者
Shi, Jiandong [1 ]
Van de Water, Ryan [1 ]
Hong, Kevin [1 ]
Lamer, Ryan B. [1 ]
Weichert, Kenneth W. [1 ]
Sandoval, Cristina M. [1 ]
Kasibhatla, Srinivas R. [1 ]
Boehm, Marcus F. [1 ]
Chao, Jianhua [1 ]
Lundgren, Karen [1 ]
Timple, Noelito [1 ]
Lough, Rachel [1 ]
Ibanez, Gerardo [1 ]
Boykin, Christina [1 ]
Burrows, Francis J. [1 ]
Kehry, Marilyn R. [1 ]
Yun, Theodore J. [1 ]
Harning, Erin K. [1 ]
Ambrose, Christine [2 ]
Thompson, Jeffrey [2 ]
Bixler, Sarah A. [2 ]
Dunah, Anthone [2 ]
Snodgrass-Belt, Pamela [2 ]
Arndt, Joseph [2 ]
Enyedy, Istvan J. [2 ]
Li, Ping [2 ]
Hong, Victor S. [2 ]
McKenzie, Andres [2 ]
Biamonte, Marco A. [1 ]
机构
[1] Biogen Idec Inc, San Diego, CA 92122 USA
[2] Biogen Idec Inc, Cambridge, MA 02142 USA
关键词
HSP90; INHIBITOR; BREAST-CANCER; ANTITUMOR ACTIVITIES; EXHIBITS POTENT; MYELOMA; DESIGN; HEAT-SHOCK-PROTEIN-90; TANESPIMYCIN; DERIVATIVES; MECHANISM;
D O I
10.1021/jm300810x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alkyne 40, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor 14 (BIIB021) that completed phase II clinical trials. Alkyne 40 is more potent than 14 in an Hsp90 alpha binding assay (IC50 = 1.1 vs 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC50 = 14 vs 38 nM). In a mouse model of gastric tumors (N87), 40 stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qdx5). Under the same conditions, 14 stops tumor growth only at 120 mg/kg, and does not induce partial regressions. Thus, alkyne 40 is approximately 20-fold more efficacious than 14 in mice.
引用
收藏
页码:7786 / 7795
页数:10
相关论文
共 50 条
  • [1] EC144, a Synthetic Inhibitor of Heat Shock Protein 90, Blocks Innate and Adaptive Immune Responses in Models of Inflammation and Autoimmunity
    Yun, Theodore J.
    Harning, Erin K.
    Giza, Keith
    Rabah, Dania
    Li, Ping
    Arndt, Joseph W.
    Luchetti, David
    Biamonte, Marco A.
    Shi, Jiandong
    Lundgren, Karen
    Manning, Anthony
    Kehry, Marilyn R.
    JOURNAL OF IMMUNOLOGY, 2011, 186 (01) : 563 - 575
  • [2] Potent Triazolothione Inhibitor of Heat-Shock Protein-90
    Feldman, Richard I.
    Mintzer, Bob
    Zhu, Daguang
    Wu, James M.
    Biroc, Sandra L.
    Yuan, Shendong
    Emayan, Kumar
    Chang, Zheng
    Chen, Deborah
    Arnaiz, Damian O.
    Bryant, Judi
    Ge, Xue Snow
    Whitlow, Marc
    Adler, Marc
    Polokoff, Mark A.
    Li, Wei-Wei
    Ferrer, Mike
    Sato, Takashi
    Gu, Jian-Ming
    Shen, Jun
    Tseng, Jih-Lie
    Dinter, Harald
    Buckman, Brad
    CHEMICAL BIOLOGY & DRUG DESIGN, 2009, 74 (01) : 43 - 50
  • [3] Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)
    Brasca, Maria Gabriella
    Mantegani, Sergio
    Amboldi, Nadia
    Bindi, Simona
    Caronni, Dannica
    Casale, Elena
    Ceccarelli, Walter
    Colombo, Nicoletta
    De Ponti, Anna
    Donati, Daniele
    Ermoli, Antonella
    Fachin, Gabriele
    Felder, Eduard R.
    Ferguson, Ronald D.
    Fiorelli, Claudio
    Guanci, Marco
    Isacchi, Antonella
    Pesenti, Enrico
    Polucci, Paolo
    Riceputi, Laura
    Sola, Francesco
    Visco, Carlo
    Zuccotto, Fabio
    Fogliatto, Gianpaolo
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (22) : 7047 - 7063
  • [4] Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
    Wu, Xinqi
    Marmarelis, Melina E.
    Hodi, F. Stephen
    PLOS ONE, 2013, 8 (02):
  • [5] Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90
    Jiang, Fen
    Wang, Hui-Jie
    Jin, Yu -Hui
    Zhang, Qiong
    Wang, Zhi-Hui
    Jia, Jian-Min
    Liu, Fang
    Wang, Lei
    Bao, Qi-Chao
    Li, Dong-Dong
    You, Qi-Dong
    Xu, Xiao-Li
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (23) : 10498 - 10519
  • [6] Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
    Erlichman, Charles
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (06) : 861 - 868
  • [7] Potent Antitrypanosomal Activities of Heat Shock Protein 90 Inhibitors In Vitro and In Vivo
    Meyer, Kirsten J.
    Shapiro, Theresa A.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (03) : 489 - 499
  • [8] Dimerization of a heat shock protein 90 inhibitor enhances inhibitory activity
    Wahyudi, Hendra
    Wang, Yao
    McAlpine, Shelli R.
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2014, 12 (05) : 765 - 773
  • [9] Heat Shock Protein 90 Inhibitors in Oncology
    Ozgur, Aykut
    Tutar, Yusuf
    CURRENT PROTEOMICS, 2014, 11 (01) : 2 - 16
  • [10] Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives
    Kim, TaeHun
    Keum, Gyochang
    Pae, Ae Nim
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (08) : 919 - 943